Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 15, 2013, Pages 4388-4392

  Yang, Christine ^a   Shen, Hong C ^a   Wu, Zhicai ^a   Chu, Hong D ^a   Cox, Jason M ^a   Balsells, Jaume ^a   Crespo, Alejandro ^a   Brown, Patricia ^a   Zamlynny, Beata ^a   Wiltsie, Judyann ^a   Clemas, Joseph ^a   Gibson, Jack ^a   Contino, Lisa ^a   Lisnock, Jeanmarie ^a   Zhou, Gaochao ^a   Garcia Calvo, Margarita ^a   Bateman, Tom ^a   Xu, Ling ^a   Tong, Xinchun ^a   Crook, Martin ^a   Sinclair, Peter ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hypertension; Mineralocorticoid receptor antagonist

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; OXAZOLIDINEDIONE DERIVATIVE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONGESTIVE HEART FAILURE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; GYNECOMASTIA; HEART FAILURE; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; IC 50; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; MICROSOME; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; MICROSOMES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MOLECULAR DOCKING SIMULATION; OXAZOLES; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, MINERALOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 84879693447     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.05.077     Document Type: Article

References (18)

1. C. Fardella, and W. Miller Annu. Rev. Nutr. 16 1996 443
2. R.S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R.J. Burns, J. Probstfield, R.T. Tsuyuki, M. White, J. Rouleau, R. Latini, A. Maggioni, J. Young, and J. Pogue Circulation 100 1999 1056
3. J.W. Funder Annu. Rev. Med. 48 1997 231
4. The RALES Investigators N. Eng. J. Med. 341 1999 709
5. F. Zannad, J.J.V. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, and B. Pitt N. Eng. J. Med. 348 2003 1309
6. J.W. Funder Hypertens. Res. 33 2010 539
7. D.A. Calhoun, and W.B. White J. Am. Soc. Hypertens. 2 2008 462
8. The RALES Investigators Am. J. Cardiol. 78 1996 902
9. A.S. Bomback, P. Muskala, E. Bald, G. Chwatko, and M. Nowicki Clin. Nephrol. 72 2009 449
10. J.S. Williams Nat. Rev. Endocrinol. 6 2010 248
11. M.K. Nishizaka, and D.A. Calhoun Curr. Hypertens. Rep. 7 2005 343
12. K. Gaddam, C. Corros, E. Pimenta, M. Ahmed, T. Denney, I. Aban, S. Inusah, H. Gupta, S.G. Lloyd, S. Oparil, A. Husain, L.J. Dell'Italia, and D.A. Calhoun Hypertension 55 2010 1137
13. F. Zannad, J.J. McMuray, H. Drexler, H. Drum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, and B. Pitt Eur. J. Heart Fail. 12 2010 617
14. M. De Gasparo, S.E. Whitebread, G. Preiswerk, X. Jeunemaitre, P. Corvol, and J. Menard J. Steroid Biochem. 32 1989 223
15. M. De Gasparo, U. Joss, H. Ramjoe, S. Whitebread, H. Haenni, L. Schenkel, C. Kraehenbuehl, M. Biollas, J. Grob, J. Schmidlin, P. Wieland, and H.U. Wehrli J. Pharmacol. Exp. Ther. 240 1987 650
16. For other non-steroidal MR antagonists, see review: M.J. Meyers, and X. Hu Expert Opin. Ther. Pat. 17 2007 17
17. http://www.discoverx.com/nhrs/prod-nhrs.php.
18. R.K. Bledsoe, K.P. Madauss, J.A. Holt, C.J. Apolito, M.H. Lambert, K.H. Pearce, T.B. Stanley, E.L. Stewart, R.P. Trump, T.M. Willson, and S.P. Williams J. Biol. Chem. 280 2005 31283